Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adicet BioLTS:0HX7 +2.82%23 14-Day RSI is 56.73 as of Aug. 31, 2026. GuruFocus rates LTS:0HX7 with a GF Score™ of 23/100 and a GF Value™ of $0.44 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,422 Biotechnology companies, Adicet Bio ranks worse than 73.21% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-08-31), Adicet Bio's 14-Day RSI is 56.73.
The industry rank for Adicet Bio's 14-Day RSI or its related term are showing as below:
LTS:0HX7's 14-Day RSI is ranked worse than 73.21% of 1422
companies
in the Biotechnology industry
Industry Median: 49.485
vs LTS:0HX7: 56.73
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Adicet Bio 14-Day RSI Related Terms
LTS:0HX7 vs OKYO, GOSS, ACRV: 14-Day RSI Comparison
For the Biotechnology subindustry, Adicet Bio's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Adicet Bio's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicet Bio (LTS:0HX7) has a 14-Day RSI of 56.73 as of Aug. 31, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Adicet Bio and its competitors. According to the industry distribution chart, Adicet Bio ranks #1041 out of 1422 companies in the Biotechnology industry, placing it in the top 73.2%.
Is Adicet Bio's 14-Day RSI too high?
Adicet Bio's current 14-Day RSI is 56.73. The Biotechnology industry median 14-Day RSI is 49.49. Adicet Bio's value of 56.73 is 14.6% above this industry median. Based on the distribution chart, Adicet Bio ranks #1041 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Adicet Bio has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's 14-Day RSI compare to OKYO and GOSS?
According to the Biotechnology industry distribution chart, Adicet Bio ranks #1041 out of 1422 companies for 14-Day RSI. This places Adicet Bio in the lower half of its industry. The industry median 14-Day RSI is 49.49. Adicet Bio's value of 56.73 is 14.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 49.49, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adicet Bio's current 14-Day RSI of 56.73 is 14.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Adicet Bio and its competitors. For the Biotechnology industry, the median 14-Day RSI is 49.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adicet Bio's current 14-Day RSI is 56.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Based on GuruFocus' analysis, Adicet Bio (LTS:0HX7) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.44, compared to a current price of $8.84 — trading 1909.1% above its estimated fair value. The current 14-Day RSI is 56.73 and 14.6% above the Biotechnology industry median of 49.49. Adicet Bio's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Adicet Bio (LTS:0HX7), the current 14-Day RSI is 56.73 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adicet Bio (LTS:0HX7) Overvalued in 2026?
Based on GuruFocus' analysis, Adicet Bio stock appears to be overvalued.
The current stock price of $8.84 is trading 1909.1% above its estimated GF Value™ of $0.44.
GuruFocus considers Adicet Bio to be Significantly Overvalued.
Key valuation signals for LTS:0HX7:
14-Day RSI: 56.73
GF Value™: $0.44 vs. price of $8.84 (1909.1% above fair value)
Industry Position: 14.6% above the Biotechnology median (#1041 of 1422)
No single metric tells the full story. See the LTS:0HX7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
23GF Score
Get the complete analysis for LTS:0HX7
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HX7 has been successfully added to your 
